Research

  • Interview: The US company appealing Europe’s rejection of daily Alzheimer’s pill

    Despite having its application for a new, daily Alzheimer’s pill rejected by Europe’s regulators the CEO of US drug company Anavex Life Sciences is appealing this decision. A Phase IIb/III trial  found over one-third of patients with mild Alzheimer’s - those with a Mini-Mental State Examination (MMSE) score of between 20 and 28 - experienced [...]

  • US$80m backs exceptional longevity study

    NIH funding of US$80m will support further research into exceptional longevity, continuing a long-running study of families whose members live far longer than statistical models predict. The funding renews support for the Long Life Family Study, an international project tracking multiple generations, including people who have lived to 100 and beyond. Researchers are seeking genetic [...]

  • Eanm launches alpha radioligand therapy award

    Eanm has launched a new award to accelerate alpha radioligand therapy research in prostate cancer, with winners to be announced at the EANM’26 Congress. Applications are now open for the 2026 EANM Young Scientist Network Award. The research award is supported by Advanced Accelerator Applications, a Novartis company, and focuses on advancing alpha radioligand therapy [...]

  • Study aims to improve recovery after cancer treatment in older people

    Researchers are studying recovery after bowel cancer treatment in older people, as the REBOUND study looks at ageing changes linked to surgery and care. The study, Resilience Breakthroughs in Older people Undergoing cancer proceDures, is examining how key "hallmarks of ageing" are affected following bowel cancer treatment in people aged 65 and over. These are [...]

  • Air pollution may directly contribute to dementia

    Long-term air pollution exposure may raise Alzheimer’s risk mainly through direct effects on the brain, a study of US Medicare records suggests. The research followed more than 27.8m US Medicare recipients aged 65 and over from 2000 to 2018, comparing estimated pollution exposure with later Alzheimer’s diagnoses. Researchers focused on PM2.5, very fine particles smaller [...]

  • Brain training reduces dementia risk, study finds

    Processing-speed brain training with booster sessions was linked to a lower dementia diagnosis risk over 20 years, according to a long follow-up study. The findings come from extended tracking of a large randomised controlled trial, where participants were assigned by chance to different training programmes or no intervention. Researchers linked trial records to US Medicare [...]

  • Space station partnership for bioprinting research

    Starlab Space has announced a partnership with Auxilium Biotechnologies to advance 3D bioprinting in orbit. Auxilium will provide orbital 3D bioprinting and biofabrication capabilities (manufacturing biological materials) aboard the Starlab space station to support research and development in regenerative medicine, implantable medical devices and tissue engineering. Regenerative medicine uses the body’s own materials to repair [...]

  • Two teas or coffees a day could lower dementia risk, experts say

    People who drink two to three cups of coffee or tea daily have a lower dementia risk, new research suggests. Health records for more than 130,000 people showed that over 40 years, those who routinely drank two to three cups of caffeinated coffee or one to two cups of caffeinated tea daily had a 15 [...]

  • Genetic influence on lifespan underestimated by half

    People are twice as likely to inherit their lifespan as previously thought, new research suggests. The genetic contribution to how long a person lives is around 50 per cent, based on health databases in Denmark and Sweden. This reflects heritability, the share of lifespan differences due to genes. For decades, many scientists believed genes and [...]

  • Aerska raises US$39m for brain RNA medicines

    Biotechnology company Aerska has raised US$39m in Series A funding to develop brain-delivered RNA medicines. The company is developing treatments for neurological diseases, including genetically driven forms of Alzheimer's disease. This takes Aerska's total funding to US$60m, months after its seed funding announcement in October 2025. The company's platform uses what it calls "brain shuttle" [...]